106 related articles for article (PubMed ID: 15205094)
1. Identification of a transcriptionally inactive p53 mutant by functional analysis of separated alleles in yeasts (FASAY) in a child osteosarcoma tumor: a case report.
Dekairelle AF; Brichard B; Delhez H; Gala JL
Pediatr Hematol Oncol; 2004 Jun; 21(4):321-8. PubMed ID: 15205094
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
3. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
[TBL] [Abstract][Full Text] [Related]
4. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
6. p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry.
Smardová J; Vagunda V; Jandáková E; Vagundová M; Koukalová H; Kovarík J; Zaloudík J
Neoplasma; 1999; 46(6):384-9. PubMed ID: 10732868
[TBL] [Abstract][Full Text] [Related]
7. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.
Duddy PM; Hanby AM; Barnes DM; Camplejohn RS
J Mol Diagn; 2000 Aug; 2(3):139-44. PubMed ID: 11229518
[TBL] [Abstract][Full Text] [Related]
8. FASAY: a simple functional assay in yeast for identification of p53 mutation in tumors.
Smardová J
Neoplasma; 1999; 46(2):80-8. PubMed ID: 10466430
[TBL] [Abstract][Full Text] [Related]
9. Screening patients for heterozygous p53 mutations using a functional assay in yeast.
Ishioka C; Frebourg T; Yan YX; Vidal M; Friend SH; Schmidt S; Iggo R
Nat Genet; 1993 Oct; 5(2):124-9. PubMed ID: 8252037
[TBL] [Abstract][Full Text] [Related]
10. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS
Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393
[TBL] [Abstract][Full Text] [Related]
11. Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids.
Isfort RJ; Cody DB; Lovell GJ; Gioeli D; Weissman BE; Doersen CJ
Mol Carcinog; 1999 May; 25(1):30-41. PubMed ID: 10331742
[TBL] [Abstract][Full Text] [Related]
12. High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast.
Pavlova S; Mayer J; Koukalova H; Smardova J
Int J Oncol; 2003 Jul; 23(1):121-31. PubMed ID: 12792784
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of transcript mutations due to transcriptional slippage in rat p53 tumor suppressor gene with the use of yeast functional assay].
Ba Y
Hokkaido Igaku Zasshi; 1999 May; 74(3):173-88. PubMed ID: 10422562
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
[TBL] [Abstract][Full Text] [Related]
16. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
17. Acetaldehyde-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a functional assay, the FASAY (functional analysis of separated alleles in yeast).
Paget V; Lechevrel M; Sichel F
Mutat Res; 2008 Mar; 652(1):12-9. PubMed ID: 18242117
[TBL] [Abstract][Full Text] [Related]
18. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
19. Detection of heterozygous nonsense mutations in genes of interest using an Escherichia coli-based stop codon assay.
Moon YJ; Kang Y; Choi JH; Lee KH
Biotechnol Appl Biochem; 2007 Feb; 46(Pt 2):137-43. PubMed ID: 16995837
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyosarcoma, osteosarcoma, and adrenocortical carcinoma in a child with a germline p53 mutation.
Khayat CM; Johnston DL
Pediatr Blood Cancer; 2004 Nov; 43(6):683-6. PubMed ID: 15390294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
